Tenon Medical, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
TNON$1.75+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
Condensed Balance Sheets (Unaudited)
(In thousands, except share data)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $4,607 | $3,756 |
| Accounts receivable, net | 1,969 | 1,698 |
| Inventory | 806 | 1,054 |
| Prepaid expenses and other current assets | 238 | 260 |
| Total current assets | 7,620 | 6,768 |
| Property and equipment, net | 901 | 918 |
| Deposits | 51 | 51 |
| Operating lease right-of-use asset | 1,389 | 131 |
| Intangible assets, net (Note 4) | 470 | 485 |
| Goodwill | 2,407 | 2,407 |
| TOTAL ASSETS | $12,838 | $10,760 |
| Liabilities and Stockholders’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $646 | $845 |
| Accrued expenses | 1,774 | 1,637 |
| Current portion of accrued commissions | 686 | 590 |
| Current portion of operating lease liability | 211 | 141 |
| Convertible notes (Note 7) | 3,480 | — |
| Derivative liability (Note 8) | 608 | — |
| Total current liabilities | 7,405 | 3,213 |
| Accrued commissions, net of current portion | 1,392 | 1,514 |
| Operating lease liability, net of current portion | 1,186 | — |
| Contingent consideration (Note 10) | 960 | 993 |
| Total liabilities | 10,943 | 5,720 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at March 31, 2026 and December 31, 2025; 204,159 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 2,622 | 2,622 |
| Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at March 31, 2026 and December 31, 2025; 86,454 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 452 | 452 |
| Common stock, $0.001 par value; 130,000,000 shares authorized at March 31, 2026 and December 31, 2025; 11,296,378 and 10,851,273 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 83,588 | 83,257 |
| Accumulated deficit | (84,778) | (81,302) |
| Total stockholders’ equity | 1,895 | 5,040 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $12,838 | $10,760 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.